Economy/Home · Economy

HLB Therapeutics Closes at 2,095 Won... Attention Turns to Follow-Up Moves After 11.1 Billion Won Rights Offering Targeting HLB

HLB Therapeutics (115450) finished trading slightly higher on the 3rd. According to the Korea Exchange, the closing price that day was 2,095 won, up 20 won (0.96%) from the previous trading day. The stock opened at 2,125 won and rose as high as 2,170 won during the session before giving back part o

Wooil Shim
Staff Reporter
5 min read
HLB Therapeutics Closes at 2,095 Won... Attention Turns to Follow-Up Moves After 11.1 Billion Won Rights Offering Targeting HLB
CBC News

HLB Therapeutics (115450) finished trading slightly higher on the 3rd. According to the Korea Exchange, the closing price that day was 2,095 won, up 20 won (0.96%) from the previous trading day.

The stock opened at 2,125 won and rose as high as 2,170 won during the session before giving back part of its gains to close the day. The intraday low was 2,085 won. Trading volume was tallied at 186,983 shares, with transaction value of approximately 398 million won.

■ 11.1 Billion Won Rights Offering Targeting HLB Completed

Market attention is also focused on the company's recent fundraising and changes in its governance structure. On the 31st of last month, HLB Therapeutics disclosed the results of its securities issuance related to a third-party allotment rights offering. The offering was conducted targeting its largest shareholder, HLB, with 6,103,185 shares issued at 1,832 won per share. The total size is approximately 11.18 billion won.

The market is expected to watch the expansion of the largest shareholder's stake following the new share issuance, along with the company's future bio business developments.

■ Global Clinical Trials for Ophthalmology Drug Candidate Through ReGenTree

HLB Therapeutics operates bio and cold chain businesses. Through its U.S. joint venture ReGenTree, the company has been conducting global clinical trials for ophthalmology drug candidates and other substances.

Based on the closing price on the 3rd, its market capitalization stands at around 180 billion won. The share price remains well below its 52-week high of 4,160 won, while its 52-week low is 1,342 won.

Going forward, the stock price is expected to be influenced mainly by changes in supply and demand following the recent rights offering and the clinical progress of its bio pipeline.

[※ This article was written for the purpose of providing information on the stock market and companies, and does not recommend the purchase or sale of specific stocks or guarantee investment returns. Stock prices may fluctuate widely depending on market conditions, corporate performance, and supply and demand, and investors may lose part or all of their principal. Investment decisions and the responsibility for them rest with the investor. This article was written with AI assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.